Chemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•19/11/2026•08:00 ET
0
Key Highlights
- ➤$150 million merger with Scipher advances; closing expected in Q1 2027
- ➤SEC declared S-4 effective; Chemomab shareholder vote scheduled for December 4, 2026
- ➤$30 million private placement planned alongside merger, with 100% warrant coverage
- ➤Nebokitug Phase 2 RA trial planned for first half of 2027, topline results projected H1 2028
- ➤Cash, equivalents and short-term deposits fell to $4.7 million at September 30
Expert Statements
Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab
“We continue to make meaningful progress toward completing our proposed merger with Scipher Medicine Corporation (“Scipher”). The SEC’s declaration of effectiveness of the Form S-4 registration statement represents an important milestone and we look forward to our shareholder meeting scheduled for December 4, 2026. Subject to shareholder approval and the satisfaction of the remaining closing conditions, we anticipate completing the transaction in the first quarter of 2027.”
Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab
“With our colleagues at Scipher, we completed a Type B Pre-Investigational New Drug (Pre-IND) interaction with the U.S. Food and Drug Administration (FDA) regarding the planned Phase 2 trial of nebokitug in RA. The FDA provided feedback that was generally consistent with our development assumptions as we advance toward a planned IND submission.”
Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab
“We believe this proposed merger provides our shareholders an opportunity to potentially realize value through the clinical advancement of nebokitug in RA, which currently represents a worldwide market estimated at approximately $24 billion annually with substantial unmet need, as well as through Scipher’s revenue-generating precision medicine business and its biopharma partnerships. We continue to work closely with our colleagues at Scipher to advance toward completion of the proposed transaction and facilitate initiation of the Phase 2 trial in RA, marking a new phase in the development of nebokitug and our anti-CCL24 platform.”
Proposed merger with Scipher Medicine with plans to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance, with closing expected in the first quarter of 2027
S-4 registration statement declared effective by SEC -- Special Meeting of Chemomab shareholders to vote on the proposed merger is scheduled for December 4, 2026
Get started
Create a free account to read the full story.
